Latest Breaking News On - தேசிய உட்செலுத்துதல் மையம் சங்கம் - Page 1 : comparemela.com

Press release content from PR Newswire. The AP news staff was not involved in its creation. Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 July 20, 2021 GMT TARRYTOWN, N.Y., July 20, 2021 /PRNewswire/ Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Regeneron’s casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19. This marks the first time the antibody cocktail, known as REGEN-COVTM in the U.S. and Ronapreve™ in other countries, has received a full approval to treat COVID-19. Emergency or temporary pandemic use authorizations are currently in place in more than 20 countries, including in the U.S., European Union, India, Switzerland and Canada.

South africaUnited statesSarah cornhillGeorged yancopoulosRegeneron velocimmuneVesna tosicPrnewswire regeneron pharmaceuticals incHuman service office of theRegeneron velocimmune technologyTeva pharmaceutical industries ltdJapan ministry of healthDepartment of healthEuropean unionRegeneron pharmaceuticals incBiomedical advanced researchRegeneron genetics center